79 results about "Tumor Cell Invasion" patented technology

The present invention relates to new compositions and methods useful for preventing, treating and diagnosing metastatic and/or invasive cancer and undesirable angiogenesis. For example, the invention relates to inhibitors of proteases that are specifically expressed in tumors, prodrugs activated in the tumor microenvironment and methods for using those inhibitors and prodrugs to inhibit angiogenesis and tumor cell invasion.

The invention discloses a multifunctional micro-fluidic chip for cell migration and an invasion assay. The multifunctional micro-fluidic chip comprises a first polydimethylsiloxane (PDMS) film layer, a second PDMS film layer and a glass substrate layer, wherein the first PDMS film layer, the second PDMS film layer and the glass substrate layer are sequentially and irreversibly bonded to form an integral structure; a first micro valve and a second micro valve are arranged on the first PDMS film layer; a first cell culture channel, a second cell culture channel and a third cell culture channel are formed in the second PDMS film layer; the first micro valve is positioned on the upper part of the joint of the first cell culture channel and the second cell culture channel; the second micro valve is positioned on the upper part of the joint of the second cell culture channel and the third cell culture channel. The multifunctional micro-fluidic chip has the advantages of being flexible and easy to operate, reliable to operate, low in manufacturing cost, high in assay success rate, multiple in functions and the like, has high biological study and economic values and is expected to provide a novel research platform for development of medicines for inhibiting tumor cell invasion in the future.

Described is a method of modulating E-cadherin mediated cell adhesion. More specifically, described is the use of hECRep1a and homologues thereof to modulate and/or control tumor cell invasiveness.

The present invention relates to the pharmaceutical application of berbamine derivative EBB in inhibiting invasive metastasis of human body tumor cell. The medicines can inhibit the metastasis of tumor cell through protecting basement membrane against destruction, and has obvious effects of lowering the expression of MMP-2 and MMP-9, strengthening the expression of TIMP and thus raising TIMP/MMP ratio. The berbamine derivative EBB is compound soluble in dilute hydrochloric acid solution, and may be prepared into corresponding water solution or powder in conventional process, into capsule or tablet via adding pharmaceutically acceptable carrier and supplementary material, or into capsule or tablet via adding supplementary medicine. The clinic dosage of berbamine derivative EBB is 10-120 mg/day, preferably 10í½80 mg/day.

The present invention discloses the tumor invasion and metastasis resisting function and application of venin cysteine proteinase inhibitor, and belongs to the field of biomedicine. Through designing and synthesizing sv-Cystatin cDNA according to 99 amino acid sequences of Chinese cobra venin Cystatin protein, cloning to pPICZ alphaA vector and transforming Pichia yeast, stable and high expression engineering bacterium GS115-sv-Cystatin is screened out. Through further inducing expression and purification, the extracorporeal bioactivity experiment shows that the recombinant sv-Cystatin protein has the functions of inhibiting the activity of papain and inhibiting the tumor cell invasion and metastasis obviously, and so do the intracorporeal experiment. The present invention also constitutes pcDNA-sv-Cystatin eukaryotic expression vector. The present invention has huge application foreground in preventing and treating tumor.

An improved method for detecting tumor cell invasion using diffusion times as short as two (2) msec incorporates diffusion weighing imaging techniques into a standard spin echo (SE) pulse sequence to minimize the effects of compartment boundary restrictions on diffusion values and corresponding MRI imaging data related to glioma invasion.

The present invention relates to methods and medicaments useful for the treatment of brain tumors by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods and medicaments are provided for reducing tumor cell proliferation and tumor growth, reducing tumor vascularity, inhibiting tumor cell invasion, improving tumor surgical margins and prolonging survival of patients with brain tumors.

The invention discloses application of a long-chain non-coding RNA (Ribose Nucleic Acid) gene LOC553103 to the preparation of nasopharyngeal darcinoma cell inhibitors. The RNA interference sequence of the LOC553103 is used for preparing a preparation for inhibiting the growth and the proliferation of nasopharyngeal darcinoma cells and preventing the tumor cell invasion migration, and is further used for preparing a preparation for inhibiting the framework assembly and reconstruction of the nasopharyngeal darcinoma cells. A powerful molecular biology tool is provided for the auxiliary treatment of the nasopharyngeal darcinoma, and profound clinical significance and important popularization and application prospects are realized.

The invention belongs to the technical field of drugs, and particularly relates to aminopeptidase N inhibitor, a preparation method and application to tumor resistance. The technical scheme includes that the aminopeptidase N inhibitor is chemically named as (S)-4-methyl-2-(3-naphthyl-1-ylmethyl-ureido)-valeryl group hydroxylamine. The constitutional formula (I) of the aminopeptidase N inhibitor is shown here. The pharmacodynamic effect of the aminopeptidase N inhibitor is evaluated by in-vitro APN (adiponectin) inhibitory experiments, in-vitro resistance to tumor cell invasion, antiangiogenesis and mouse in-vivo resistance to melanoma manual transfer and antiangiogenesis experiments.

The invention discloses application of HIP-55 protein to development of tumor inhibition drugs. DNA molecules encoding and interfering HIP-55 protein from expressing siRNA are inserted into an expression vector to obtain a recombinant vector; the amino acid sequence of the HIP-55 protein is a sequence II in a sequence table; the invention also provides application of HIP-55 protein or the recombinant vector containing the HIP-55 protein coding gene to preparation of products having the following functions of (1) promoting tumor cell migration and/or (2) promoting tumor cell invasion. Experiments prove that the HIP-55 protein gene is overexpressed in lung cancer cells to promote tumor formation, lung cancer cell migration and lung cancer cell invasion; therefore, the HIP-55 provides a new target for clinical diagnosis, treatment and development of new drugs and can be used for screening, developing and/or designing products for prevention and/or treatment of tumors.

The invention discloses RGD tetrapeptide modified beta-carboline acyl-tryptophan and discloses a preparation method, a nanostructure, an effect of resisting tumor cell adhesion, an effect of resisting tumor cell invasion, an effect of resisting tumor cell migration, an anti-rumor effect and an effect of inhibiting tumor transfer to lung. The invention discloses application thereof in medicine. The formula is as shown in the specification.

The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors.

This invention relates to a carrier for stable expression of VEGF shRNA in mammal cells, and its application as an inhibitor to tumor cell invasion and metastasis. Research results show that after the reansfection to tumor cells by the pCD-VEGF carrier designed for VEGF gene, the invasion ability of tumor cells to the matrix membrane is weakened, the mobility of tumor cells is limited, and the growth of tumor cells in nude mouse is obviously suppressed. The pCD-VEGF carrier has a potential application in effective antitumor drugs.

Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.

The invention discloses application of EphrinA1 in tumor development, metastasis, treatment and prognosis of patients. The invention discloses that EphrinA1 is involved in the process of tumor growth,invasion and metastasis. The high expression of EphrinA1 in a gastric cancer tissue leads to poor prognosis of gastric cancer patients, and targeted knockdown or knockout of EphrinA1 expression can significantly inhibit the invasion ability of gastric cancer cells and the metastasis ability of the gastric cancer cells in mice. The invention utilizes a function that an antibody targeting EphrinA1blocks EphrinA1, and can effectively inhibit the invasion ability of the gastric cancer cells. The invention finds that EphrinA1 has an important application value in tumor therapy and can be used asa target for antitumor drugs.

Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.

The present invention provides compositions and methods of using curcumin or curcumin derivatives or analogs to activate the pro-apoptotic enzymes caspase-3/7 in cancer cells. The present invention also provides formulations of curcumin or derivatives or analogs with increased solubility or improved bioavailability. The formulations may be administered to a subject such that high concentrations of therapeutically effective curcumin compounds resuit in the subject's bloodstream. The invention thus involves the use of curcumin or curcumin derivatives or analogs to diminish cancer cell growth, decrease tumor size, prevent tumor formation, and Curcumin Carrier to reduce or prevent cancer or tumor cell invasion or metastasis into a tissue, e.g., into the nervous System and especially the brain, of a subject. The instant invention may be used prophylactically to prevent tumor formation or metastasis, as a monotherapy to treat existing tumors, after surgery to prevent recurrence of tumors or in conjunction with conventional cancer therapies to improve patient prognosis and reduce side-effects.

The invention discloses a preparation method and application of a dual-regulation supramolecular assembly for inhibiting tumor invasion and diffusion. A construction unit is a nano supramolecular fiber aggregate taking hyaluronic acid modified by beta-cyclodextrin as a host, magnetic nano-particles modified by octapeptide as a guest, and constructed through supramolecular host-guest interaction. The supramolecular assembly provided by the invention has the advantages that the supramolecular assembly is directionally aggregated under the induction of a geomagnetic field or weak magnetic field,and can be optically controlled to induce aggregation; on the other hand, the supramolecular assembly can specifically attract cancer cells in a nano-fiber net-like structure, and can cause damage tomitochondria; the preparation method of the supramolecular assembly with double regulation of magnetic field and illumination is simple, easy to implement and low in raw material cost, so that the supramolecular assembly has a wide application prospect in the field of tumor treatment, especially in the aspect of actively inhibiting tumor cell invasion and diffusion.

The invention belongs to the field of medical technology and discloses a genistein derivative with a structure shown by formula I in the specification or a pharmaceutically acceptable salt thereof. The invention also discloses an application of the genistein derivative or the pharmaceutically acceptable salt thereof in preparing a tumor treating medicine, an application in preparing an inflammation-related tumor treating medicine and an application in preparing a medicine inhibiting tumor cell invasion and migration. The genistein derivative disclosed by the invention generates a growth inhibiting and killing effect on tumor cells to realize an anti-tumor effect and has broad-spectrum anti-tumor activity while the effect is relatively good; the genistein derivative promises a perfect treatment effect on the AOM/DSS induced inflammation related tumor; and with relatively good ability of inhibiting tumor cell invasion and migration, the genistein derivative can be used for preparing a medicine inhibiting tumor migration and can be made into tumor migration inhibiting medicines of various dosage forms, thereby providing a better choice for tumor patients.

The invention relates to the fields of tumor molecular biology and tumor drug treatment. The invention provides a use of CD133 as a tumor cell invasion marker and an application with CD133 as a target for screening drugs that inhibit tumor cell invasion. According to the invention, technologies of plasmid transfection, rat glioma model establishment, vivo imaging, immunohistochemistry and Transwellare employed to verify the high expression of the CD133 in invasion foci around glioma, and it is verified that highly-expressed glioma cells are more susceptible to invasion in vivo and in vitro. Further research indicates thatthe CD133 makes glioma more susceptible to invasion by improving tumor cell migration capability and altering cytoskeletal. The CD133 can provide tumor treatment programme selection and antitumor drug screening with new ideas.

The invention provides an application of an miR-10a-mediated tumor-associated fibroblast to a product with at least one of the following functions (1) to (6): (1) inhibiting tumor cell proliferation,(2) promoting tumor cell apoptosis, (3) inhibiting tumor cell migration, (4) inhibiting tumor cell invasion, (5) inhibiting tumor cell sphere formation, and (6) preventing and/or treating a tumor, wherein the tumor is a colorectal cancer; a tumor cell is a colorectal cancer cell; and a nucleotide sequence of miR-10a is as shown in SEQ ID NO:1. According to the application, the effect of the overexpressed miR-10a on liver fibroblast activity in vitro is known and understood from a new perspective, and the effect of a change of the liver fibroblast activity on formation of metastasis in liver bythe colorectal cancer cell is thoroughly discussed, so as to provide a molecular mechanism of hepatic metastasis in the colorectal cancer with an epigenetic basis and to provide a new idea and targetfor prevention and treatment of the colorectal cancer.

The invention discloses a traditional Chinese medicinal effective ingredient composition and application thereof to preparation of anti-tumor metastasis drugs. The traditional Chinese medicinal effective ingredient composition comprises effective dosage of total salvianolic acids, total ginsenoside and ginseng polysaccharides, as well as pharmaceutically acceptable carriers. The important point of the invention is the discovery that the composition can effectively inhibit tumor cell invasion and migration, and significantly reduce the tumor cell ERK1/2 phosphorylation level; a preparation prepared according to the matching ratio range provided by the invention has a better curative effect, and overcomes the defects that the traditional drug matching is unclear in active ingredients, the quality is uncontrollable, and accordingly the treating effect is undefined. Therefore, the traditional Chinese medicinal effective ingredient composition has application prospects to the preparation of anti-tumor metastasis drugs.